SCHEMBL7041929

SCHEMBL7041929

Cc1ccc(-c2ccc(CNC(=O)c3cc(NC(=O)c4ccccc4N4CCCC4)cn3C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
GAA P10253 1/20 0.50
LMNA P02545 6/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 3/20 0.46
POLB P06746 2/20 0.45
ITGA4 P13612 1/20 0.44
ITGB7 P26010 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
XBP1 P17861 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7036532 0.92 POLB (0.54) L3MBTL1GAALMNATP53POLB
SCHEMBL7042872 0.87 POLB (0.43) L3MBTL1GAALMNAMAPTTP53
SCHEMBL7039859 0.85 CHRNB2 (0.47) L3MBTL1LMNATP53POLBKDM4E
SCHEMBL7039230 0.83 CHRNB2 (0.51) L3MBTL1LMNATP53POLBKDM4E
SCHEMBL7037234 0.81 RXFP1 (0.46) L3MBTL1LMNAPOLBITGA4ITGB7
SCHEMBL7039202 0.81 ALDH1A1 (0.64) L3MBTL1GAALMNAPOLBKDM4E
SCHEMBL7041084 0.81 LMNA (0.46) LMNAMAPTTP53POLBMEN1
SCHEMBL7041358 0.80 ALDH1A1 (0.51) L3MBTL1GAALMNATP53POLB
SCHEMBL6679276 0.79 GAA (0.56) L3MBTL1GAAMAPTTP53POLB
SCHEMBL6674202 0.79 ALDH1A1 (0.47) L3MBTL1GAALMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN L3MBTL1 2563/4885GAA 276/4885LMNA 1024/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 L3MBTL1 2996/4885GAA 1651/4885LMNA 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.